Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 74, n° 6
pages 1252-1254 (juin 2016)
Doi : 10.1016/j.jaad.2016.01.011
Research Letters

Use of topical retinoids by dermatologists and non-dermatologists in the management of acne vulgaris
 

Sandra Pena, BA a, Dane Hill, MD a, Steven R. Feldman, MD, PhD a, b, c,
a Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 
b Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC 
c Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC 

Correspondence to: Steven R. Feldman, MD, PhD, Department of Dermatology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071Department of DermatologyWake Forest School of MedicineMedical Center BlvdWinston-SalemNC27157-1071

 Funding source: None.
 Conflict of interest: The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories, L.P. Dr Feldman is a speaker for Janssen and Taro. He is a consultant and speaker for Galderma, Stiefel/GlaxoSmithKline, Abbott Labs, and Leo Pharma Inc. Dr Feldman has received grants from Galderma, Janssen, Abbott Labs, Amgen, Stiefel/GlaxoSmithKline, Celgene, and Anacor. He is a consultant for Amgen, Baxter, Caremark, Gerson Lehrman Group, Guidepoint Global, Hanall Pharmaceutical Co Ltd, Kikaku, Lilly, Merck & Co Inc, Merz Pharmaceuticals, Mylan, Novartis Pharmaceuticals, Pfizer Inc, Qurient, Suncare Research, and Xenoport. He is on an advisory board for Pfizer Inc. Dr Feldman is the founder and holds stock in Causa Research and holds stock and is majority owner in Medical Quality Enhancement Corporation. He receives royalties from UpToDate and Xlibris. Dr Hill's translational research is funded by Janssen Pharmaceuticals. Sandra Pena has no conflict of interest to declare.
 This study was declared exempt by the Wake Forest School of Medicine Institutional Review Board.


Top of the page

© 2016  American Academy of Dermatology, Inc.@@#104156@@